Bronchial Infection in Patients With COPD and Frequent Exacerbations.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03259022|
Recruitment Status : Unknown
Verified August 2017 by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.
Recruitment status was: Recruiting
First Posted : August 23, 2017
Last Update Posted : August 23, 2017
- Innate immunity is altered in certain patients with COPD and frequent exacerbations, a fact that makes them more susceptible to being infected by bacteria.
- The electronic nose is able to detect patterns of specific VOCs for exacerbations of infectious origin.
|Condition or disease|
|Pulmonary Disease, Chronic Obstructive|
Bronchial infection has been described as the leading cause of COPD exacerbations. Different studies with invasive endoscopic techniques have demonstrated the presence of bacteria in the air in 40-70% of exacerbations of the disease. In addition, these patients have a higher concentration of cells and proinflammatory cytokines in the airway. This increased inflammation is associated with more frequent and more severe exacerbations, which worsen this vicious circle.
It is not known why some patients with COPD are more susceptible than others to bronchial, acute or chronic infection. Recent studies have suggested the importance of lung innate immunity, both humoral (proteins with antibiotic activity, inflammatory mediators) and cell (neutrophils, macrophages) as the key to the defense of the lung against infectious agents external factor. There may be a bidirectional relationship between immune response and bronchial infection in COPD exacerbations.
Te main objectives of our study are: 1. To study the expression of mucin, PAM and TLR in the airway of patients with COPD and frequent exacerbations (FE) and its relationship with the infection of the airway. 2. Determine the patterns of volatile organic compounds (VOCs) detected by electronic nose associated with bronchial infection in patients with COPD and FE.
Secondary objectives: 1. To study the relationship between the expression of mucin, PAM and TLR with pulmonary and systemic inflammation. 2. To study the relationship between the expression of mucin, PAM and TLR with bronchial bacterial load. 3. To study the expression of mucin, PAM and TLR at the time of COPD exacerbations and subsequent clinical phase stability. 4. Determine VOC patterns for specific pathogens (H. influenzae, S. pneumoniae, P. aeurginosa). 5. To study the time evolution of patterns of VOCs after a COPD exacerbation.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Bronchial Infection in Patients With COPD and Frequent Exacerbations; Role of Innate Immunity and the Use of an Electronic Nose for Diagnosis.|
|Study Start Date :||November 2016|
|Estimated Primary Completion Date :||July 2019|
|Estimated Study Completion Date :||December 2019|
- Relationship between infection and airway innate immunity of patients with COPD and frequent exacerbations. [ Time Frame: 6 months ]Mucine levels will be determined with ELISA kits
- Association between volatile organic compounds (VOCs) detected by an electronic nose and bronchial infection in patients with COPD and frequent exacerbations. [ Time Frame: 6 months ]The patterns of specific volatile organic compounds in echaled air will be determined with electronic nose device.
- Relationship between airway innate immunity and systemic inflammation. [ Time Frame: 6 months ]Mucin levels will be determined with ELISA kits
- Relationship between airway innate immunity and bronchial bacterial load. [ Time Frame: 6 months ]Mucin levels will be determined with ELISA kits.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03259022
|Contact: Oriol Sibila, PhD||932 91 90 firstname.lastname@example.org|
|Hospital de la Santa Creu i Sant Pau||Recruiting|
|Barcelona, Spain, 08026|
|Contact: Oriol Sibila, PhD 932 91 90 00 email@example.com|
|Principal Investigator:||Oriol Sibila, PhD||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|